keyword
MENU ▼
Read by QxMD icon Read
search

Filgrastim

keyword
https://www.readbyqxmd.com/read/29656748/nivolumab-induced-severe-pancytopenia-in-a-patient-with-lung-adenocarcinoma
#1
Kentaro Tokumo, Takeshi Masuda, Takahiko Miyama, Shinichiro Miura, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Taku Nakashima, Shintaro Miyamoto, Takashi Yoshida, Hiroshi Iwamoto, Kazunori Fujitaka, Hironobu Hamada, Noboru Hattori
Severe leukopenia, thrombocytopenia, and bi-cytopenia due to nivolumab have been reported. In this report, we present the first case of nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma. A 56-year-old Japanese man with lung adenocarcinoma received nivolumab therapy as second-line treatment. After 3 cycles of this therapy, although computed tomography (CT) showed a reduced tumor size, laboratory findings revealed pancytopenia and a bone marrow biopsy showed a severely hypoplastic marrow...
May 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29651919/the-incidence-and-timing-of-leukocyte-overshoot-after-pegfilgrastim-administration
#2
Eiseki Usami, Michio Kimura, Mina Iwai, Makiko Go, Hiroki Asano, Shoya Takenaka, Shino Adachi, Tomoaki Yoshimura
Introduction Pegfilgrastim is a PEGylated formulation of filgrastim with a long half-life. It is highly convenient and less burdensome for patients. However, white blood cell count may temporarily increase after administration; in particular, a leukocyte overshoot may be observed. The present study retrospectively examined the incidence and timing of leukocyte overshoot after pegfilgrastim administration. Patients and methods Fifty-five patients (118 occasions of pegfilgrastim) were evaluated. Leukocyte overshoot was defined as white blood cell count ≥10,000/mm3 exceeding the reference value...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29626003/probable-fidaxomicin-induced-pancytopenia
#3
Samantha Axtell, Aisha Shokoya, Christine Yocum
PURPOSE: A case of pancytopenia in a patient receiving treatment with fidaxomicin for Clostridium difficile infection (CDI) is described. SUMMARY: A 33-year-old Caucasian woman was admitted to the hospital with a chief complaint of loose stools occurring approximately 7 times a day; she also reported fever, nausea, diffuse abdominal pain, and fatigue. The patient had a history of recurrent CDI, recurrent urinary tract infections, nephrolithiasis, chronic hepatitis C, and endometriosis...
April 15, 2018: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/29574886/patient-characteristics-associated-with-peglyated-interferon-alfa-2a-induced-neutropenia-in-chronic-hepatitis-c-patients
#4
Nagham N Hindi, Mohammad I Saleh
Neutropenia is a hematologic disorder commonly reported in patients with chronic hepatitis C virus (HCV) infection treated with pegylated interferon alfa-2a (PEG-IFN α-2a). The objective of the present project is to identify patient characteristics associated with neutropenia in hepatitis C patients. Demographic, clinical, and genetic data from 715 patients with chronic HCV infection treated with PEG-IFN α-2a and ribavirin. The outcome variable was the development of grade 3 or 4 neutropenia, defined as the decrease in neutrophil counts below 1x109 /L anytime during study...
March 25, 2018: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/29561198/reply-re-cost-efficiency-analyses-for-the-us-of-biosimilar-filgrastim-sndz-reference-filgrastim-pegfilgrastim-and-pegfilgrastim-with-on-body-injector-in-the-prophylaxis-of-chemotherapy-induced-febrile-neutropenia
#5
Ali McBride, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham, Sanjeev Balu
No abstract text is available yet for this article.
March 21, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29552362/severe-hyperthyroidism-complicated-by-agranulocytosis-treated-with-therapeutic-plasma-exchange-case-report-and-review-of-the-literature
#6
Vishnu Garla, Karthik Kovvuru, Shradha Ahuja, Venkatataman Palabindala, Bharat Malhotra, Sohail Abdul Salim
Aim: To present a case of Graves' disease complicated by methimazole induced agranulocytosis treated with therapeutic plasma exchange (TPE) and review of the literature. Case Presentation: A 21-year-old patient with a history of Graves' disease presented to the endocrine clinic. His history was significant for heat intolerance, weight loss, and tremors. Upon examination he had tachycardia, smooth goiter, thyroid bruit, and hyperactive reflexes. He was started on methimazole and metoprolol and thyroidectomy was to be done once his thyroid function tests normalized...
2018: Case Reports in Endocrinology
https://www.readbyqxmd.com/read/29547012/re-cost-efficiency-analyses-for-the-us-of-biosimilar-filgrastim-sndz-reference-filgrastim-pegfilgrastim-and-pegfilgrastim-with-on-body-injector-in-the-prophylaxis-of-chemotherapy-induced-febrile-neutropenia
#7
Mark Bensink, Christine Edwards, Charles Bowers, Jon Campbell
No abstract text is available yet for this article.
March 16, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29535105/filgrastim-enhances-t-cell-clearance-by-antithymocyte-globulin-exposure-after-unrelated-cord-blood-transplantation
#8
Coco de Koning, Julie-Anne Gabelich, Jurgen Langenhorst, Rick Admiraal, Jurgen Kuball, Jaap Jan Boelens, Stefan Nierkens
Residual antithymocyte globulin (ATG; Thymoglobulin) exposure after allogeneic hematopoietic (stem) cell transplantation (HCT) delays CD4+ T-cell immune reconstitution (CD4+ IR), subsequently increasing morbidity and mortality. This effect seems particularly present after cord blood transplantation (CBT) compared to bone marrow transplantation (BMT). The reason for this is currently unknown. We investigated the effect of active-ATG exposure on CD4+ IR after BMT and CBT in 275 patients (CBT n = 155, BMT n = 120; median age, 7...
March 13, 2018: Blood Advances
https://www.readbyqxmd.com/read/29532546/adjuvant-continuous-metronomic-adriamycin-cyclophosphamide-followed-by-weekly-nab-paclitaxel-for-high-risk-early-stage-breast-cancer
#9
Eunpi Cho, Qian Wu, Lena Rubinstein, Hannah Linden, Julie Gralow, Jennifer Specht, Vijayakrishna Gadi, Georgiana Ellis
Many studies have sought to optimize the dosing schedule of adjuvant chemotherapy in early-stage breast cancer. Here, we assessed the use of continuous metronomic weekly doxorubicin plus daily oral cyclophosphamide (AC) with continuous G-CSF growth factor support for 12 weeks followed by weekly nab-paclitaxel (nP) for 12 weeks. A nonrandomized phase II clinical trial was designed to assess (1) DFS at 2 years, (2) dose delivered, (3) use of nP in the adjuvant setting, and (4) toxicities. The dosing of A was 24 mg/m2 IV weekly and C was 60 mg/m2 oral daily (with scheduled filgrastim 5mcg/kg 6 days/week); nP, 100 mg/m2 IV weekly...
March 13, 2018: Breast Journal
https://www.readbyqxmd.com/read/29515065/-efficacy-and-safety-of-biosimilar-filgrastim-for-autologous-peripheral-blood-stem-cell-harvest-and-transplantation-a-single-institutional-retrospective-analysis
#10
Masaki Iino, Takeo Yamamoto
Three biosimilar filgrastim products are currently available in Japan. Among these, the safety and efficacy of two imported drugs for autologous peripheral blood stem cell harvest (autoPBSCH) and autologous peripheral blood stem cell transplantation (autoPBSCT) have been studied widely; however, evidence of the safety and efficacy of domestically manufactured filgrastim is limited. Therefore, we compared the efficacy and safety of domestic biosimilar filgrastim (BF1, n=23) with those of originator filgrastim (OF, n=21) for autoPBSCH and autoPBSCT...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29492357/adequate-neutrophil-responses-and-non-inferior-clinical-outcomes-can-be-achieved-by-a-two-day-course-of-low-dose-filgrastim-a-retrospective-single-institution-experience
#11
Raj Singh, Henry Heisey, Ahmed G Elsayed, Maria T Tirona
Background Filgrastim is used in the setting of chemotherapy-induced neutropenia to stimulate recovery of bone marrow, which allows for further chemotherapy administration without delay. The recommended dose is 5 ug/kg. The commercially available vials of the drug come in two strengths; 300 ug and 480 ug. Due to these limitations in dosage formulations, it is a frequent occurrence to administer a lower dosage to patients weighing more than 60 kg, in whom the ideal dose would have been more than 300 ug but less than 480 ug...
December 19, 2017: Curēus
https://www.readbyqxmd.com/read/29475405/interstitial-pneumonitis-and-myelosuppression-associated-to-mitomycin-c-urinary-tract-instillations-a-case-report
#12
Montserrat Rodriguez-Reyes, Javier Marco-Hernandez, Pedro Castro-Rebollo, Dolors Soy-Muner
Mitomycin C as a treatment for superficial bladder carcinomas and upper urinary tract tumours has been linked to local adverse events. Systemic toxicity has been documented for just a very few cases. This report presents a case of interstitial pneumonitis accompanied by myelosuppression in a 74-year-old patient after receiving the fifth administration of mitomycin C through a ureteral catheter as a treatment for left kidney pyelocaliceal urothelial carcinoma. Therefore, suspecting mitomycin C toxicity, urinary tract instillations were discontinued, and intravenous filgrastim and methylprednisolone were initiated...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29472357/plerixafor-enables-the-safe-rapid-efficient-mobilization-of-haematopoietic-stem-cells-in-sickle-cell-disease-patients-after-exchange-transfusion
#13
Chantal Lagresle-Peyrou, François Lefrère, Elisa Magrin, Jean-Antoine Ribeil, Oriana Romano, Leslie Weber, Alessandra Magnani, Hanem Sadek, Clémence Plantier, Aurélie Gabrion, Brigitte Ternaux, Tristan Félix, Chloé Couzin, Aurélie Stanislas, Jean-Marc Tréluyer, Lionel Lamhaut, Laure Joseph, Marianne Delville, Annarita Miccio, Isabelle André-Schmutz, Marina Cavazzana
Sickle cell disease is characterized by chronic anaemia and vaso-occlusive crises, which eventually lead to multi-organ damage and premature death. Haematopoietic stem cell transplantation is the only curative treatment but it is limited by toxicity and poor availability of HLA-compatible donors. A gene therapy approach based on the autologous transplantation of lentiviral-corrected haematopoietic stem and progenitor cells was shown to be efficacious in one patient. However, alterations of the bone marrow environment and the red blood cells' properties hamper the harvesting and immunoselection of patient stem cells from bone marrow...
February 22, 2018: Haematologica
https://www.readbyqxmd.com/read/29446445/lenograstim-5-%C3%A2%C2%B5g-kg-is-not-superior-to-biosimilar-filgrastim-10-%C3%A2%C2%B5g-kg-in-lymphoma-patients-undergoing-peripheral-blood-stem-cell-mobilization-after-chemotherapy-preliminary-results-from-a-prospective-randomized-study
#14
Francesco Marchesi, Michele Vacca, Diana Giannarelli, Francesco Ipsevich, Annino Pandolfi, Svitlana Gumenyuk, Daniela Renzi, Francesca Palombi, Francesco Pisani, Atelda Romano, Antonio Spadea, Elena Papa, Marco Canfora, Luca Pierelli, Andrea Mengarelli
BACKGROUND: Randomized trials comparing chemomobilization efficiency between lenograstim and biosimilar filgrastim are lacking. Our previous retrospective study suggested that lenograstim could be more effective than biosimilar filgrastim when used at the same conventional dosage (5 µg/kg) only in lymphoma patients undergoing peripheral blood stem cell mobilization. We planned a prospective randomized study comparing lenograstim 5 µg/kg with biosimilar filgrastim 10 µg/kg to verify the hypothesis of lenograstim superiority even at half the dosage (stress test)...
February 15, 2018: Transfusion
https://www.readbyqxmd.com/read/29434148/pseudogout-attack-after-pegfilgrastim-administration-in-anaplastic-large-cell-lymphoma
#15
Mayumi Hatayama, Katsuya Ikuta, Masatomo Ishioh, Takeshi Saito, Yasumichi Toki, Masayo Yamamoto, Motohiro Shindo, Yoshihiro Torimoto, Toshikatsu Okumura
A 67-year-old man with relapsed anaplastic large cell lymphoma received salvage chemotherapy, and pegfilgrastim was used to prevent febrile neutropenia. On day 18 of chemotherapy, he developed a pseudogout attack. Although the first symptoms improved, another pseudogout attack occurred when he received the second course of chemotherapy and pegfilgrastim. Filgrastim was then used for the third course of chemotherapy, and a pseudogout attack did not occur. The serum granulocyte-stimulating factor (G-CSF) level was extremely elevated only when pegfilgrastim was used, suggesting a relationship between pseudogout and G-CSF...
February 9, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29430414/pattern-and-impact-of-drugs-targeted-toward-toxicity-amelioration-in-patients-receiving-cancer-chemotherapy
#16
Shruti Singh, Prashant Kumar Singh
Background: Drug therapy today is remarkably safe and efficacious. Still, some drugs - particularly anticancer drugs - are fraught with numerous adverse drug reactions (ADRs), severely jeopardizing quality of life of cancer patients. Fortunately, most of these ADRs are preventable provided adequate prophylactic drugs are administered along with chemotherapy. Aims: The aim of this study is to assess the pattern and impact of cytoprotective prophylactic drugs on anticancer ADRs in patients receiving cancer chemotherapy...
January 2018: Perspectives in Clinical Research
https://www.readbyqxmd.com/read/29411131/filgrastim-use-in-patients-receiving-chemotherapy-for-early-stage-breast-cancer-a-survey-of-physicians-and-patients
#17
John Hilton, Lisa Vandermeer, Marta Sienkiewicz, Sasha Mazzarello, Brian Hutton, Carol Stober, Dean Fergusson, Phillip Blanchette, Anil A Joy, A Brianne Bota, Mark Clemons
PURPOSE: Despite its widespread use as primary febrile neutropenia (FN) prophylaxis during chemotherapy for early-stage breast cancer, the optimal duration of daily filgrastim is unknown. Using the minimum effective duration may improve patient comfort and acceptability while reducing costs. Yet, suboptimal dosing may also negatively impact patient care. A survey was performed to obtain information regarding current practices for granulocyte colony-stimulating factor (G-CSF) use. METHODS: Canadian oncologists involved in the treatment of breast cancer patients, as well as patients who had received neo/adjuvant chemotherapy for breast cancer, were surveyed...
February 6, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29410296/low-cd34-cell-doses-are-associated-with-increased-cost-and-worse-outcome-following-of-tandem-autologous-stem-cell-transplantation-in-patients-with-relapsed-or-refractory-germ-cell-tumors
#18
Mustafa A Hyder, W Scott Goebel, Kirsten D Ervin, Jennifer E Schwartz, Michael J Robertson, Teresa C Thakrar, Costantine Albany, Sherif S Farag
Tandem autologous stem cell transplantation (ASCT) improves long-term survival of platinum-refractory germ cell tumors (GCT) patients. Studies, predominantly in lymphoma, showed that CD34+ cell doses > 5.0 x 106/kg/single transplant lead to decreased resource utilization. As most GCT patients have received prior cisplatin-based treatment, collecting >10x106 CD34+ cells/kg is challenging. We analyzed the effect of CD34+ cell dose on resource utilization and outcome of in 131 GCT patients, median age 29...
February 2, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29403286/biosimilar-filgrastim-vs-filgrastim-a-multicenter-nationwide-observational-bioequivalence-study-in-patients-with-chemotherapy-induced-neutropenia
#19
Alper Sevinç, Metin Özkan, Ahmet Özet, Faysal Dane, Berna Öksüzoğlu, Abdurrahman Işıkdoğan, Feyyaz Özdemir, Doğan Uncu, Mahmut Gümüş, Türkkan Evrensel, Arzu Yaren, Oğuz Kara, Salim Başol Tekin
Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim in patients with chemotherapy-induced neutropenia. Patients and methods: This multicenter, observational study was conducted at 14 centers. The study included 337 patients experiencing neutropenia under chemotherapy. Patients were given either filgrastim 30 MIU or 48 MIU (Neupogen®) or biosimilar filgrastim 30 MIU (Leucostim®). Data regarding age, chemotherapeutic agents used, number of chemotherapy courses, previous diagnosis of neutropenia, neutrophil count of patients after treatment, medications used for the treatment of neutropenia, and duration of neutropenia were collected...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29401143/false-positive-18f-fdg-pet-ct-due-to-filgrastim-that-induced-extramedullary-liver-hematopoiesis-in-a-burkitt-lymphoma
#20
Anna Margherita Maffione, Lucia Rampin, Paolini Rossella, Sara Pecori, Patrick M Colletti, Domenico Rubello
We report a case of Burkitt lymphoma with largely extranodal disease localizations at staging. Chemotherapy was given, thus obtaining a complete metabolic response in all previous disease sites as shown at a control PET, however associated to the appearance of new focal uptake areas in the liver; these findings were confirmed at US and MRI. Chemotherapy determined also neutropenia that was treated by filgrastim, followed by a prompt and important medullary response. Liver biopsy revealed extramedullary hematopoiesis, probably filgrastim induced...
February 3, 2018: Clinical Nuclear Medicine
keyword
keyword
81469
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"